Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the apex study
Key Points
Evaluate the early effects of aflibercept-ayyh on visual and anatomical outcomes in retinal vascular diseases.
Real-world experience observation
Assessment of visual and anatomical improvements
Monitoring short-term safety profile
Significant early visual improvements observed
Notable anatomical improvements reported
Favorable short-term safety profile noted
Abstract
Aflibercept-ayyh demonstrated significant early visual and anatomical improvements across major retinal vascular diseases with a favorable short-term safety profile.